Episodic Migraine Clinical Trial
Official title:
A 12-week Double-blind, Randomized, Multi-center Study Comparing the Efficacy and Safety of Once Monthly Subcutaneous AMG 334 Against Placebo in Adult Episodic Migraine Patients (EMPOwER)
This study is to evaluate the efficacy and safety of AMG334 in adult patients with episodic migraine
This study used a single-cohort, 3-treatment arm, randomized, double-blind study design in adult patients with episodic migraine. The subjects were randomized to receive either erenumab or placebo in a 2:3:3 ratio (erenumab 140 mg: erenumab 70 mg: placebo). A screening period of 2 weeks was used to assess initial eligibility, followed by a 4-week baseline period. After randomization/Day 1, visits occurred at four week intervals until Week 12, which was the End of Treatment. The final visit, Last Patient Last Visit was a Safety Follow-Up visit, which occurred 12 weeks later, at Week 24. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06047457 -
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
|
Phase 3 | |
Completed |
NCT02569853 -
DFN-11 Injection in Episodic Migraine With or Without Aura
|
Phase 3 | |
Completed |
NCT00719134 -
The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache
|
Phase 4 | |
Completed |
NCT03700320 -
Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
|
Phase 3 | |
Terminated |
NCT04936061 -
Transnasal Cooling for Migraine
|
N/A | |
Recruiting |
NCT05281770 -
Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study
|
||
Recruiting |
NCT05042037 -
Probiotics as Adjunctive Migraine Prophylaxis
|
N/A | |
Recruiting |
NCT04628429 -
CGRP Inhibition, Autonomic Function, and Migraine
|
||
Active, not recruiting |
NCT05028569 -
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine
|
Phase 3 | |
Withdrawn |
NCT01257893 -
Aspirin Resistance in Women With Migraine
|
N/A | |
Recruiting |
NCT06051604 -
Mi-Helper Transnasal Cooling for Acute Treatment of Migraine
|
N/A | |
Completed |
NCT03132233 -
Energy for the Brain
|
N/A | |
Completed |
NCT03939312 -
Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine
|
Phase 3 | |
Completed |
NCT03927144 -
Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients
|
Phase 4 | |
Recruiting |
NCT06248671 -
Prophylactic Treatment With Atorvastatin for Episodic Migraine.
|
Phase 2 | |
Recruiting |
NCT05711394 -
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
|
Phase 3 | |
Recruiting |
NCT05449145 -
The Effects of Vitamin D Plus Omega-3 Polyunsaturated Fatty Acids in Patients With Episodic Migraine
|
N/A | |
Completed |
NCT04031781 -
The Role of Left Prefrontal Transcranial Magnetic Stimulation in Episodic Migraine Prophylaxis
|
N/A | |
Completed |
NCT05264129 -
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine
|
Phase 4 | |
Completed |
NCT04740827 -
Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.
|
Phase 3 |